Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086526 · ClinicalTrials.gov registry record · Phase 1
Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT02086526: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02086526 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02086526, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's effect on insulin sensitivity and endothelial function. This pilot project will be the foundation for developing tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug targets.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02086526
The ClinicalTrials.gov registry entry for NCT02086526 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT02086526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02086526 about?
NCT02086526 is a clinical study titled "Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)". The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's eff...
What is the current status of trial NCT02086526?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2014-03. Estimated completion is 2016-11-20.
What interventions are being tested in trial NCT02086526?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT02086526?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.